Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

Hematopoietic stem cell transplantation can cure patients with blood cancer and other underlying diseases. αβ-T cell and B cell depletion has been introduced to decrease GVHD and PTLD and has demonstrated effectiveness for hematologic malignancies and non-malignant diseases additionally increasing the donor pool as to allow for haploidentical transplant to safely occur. While solid tumors can be highly chemotherapy sensitive, many remain resistant and require multimodalities of treatment. Immunotherapy has been developed to harness the immune system in fighting solid tumors, though not all ha

Trial Details

NCT ID

NCT06625190

Phase

PHASE1 / PHASE2

Sponsor

University of Florida

Status

RECRUITING

Cancer Type

Osteosarcoma Sarcoma

Interventions

Miltenyi CliniMACS Prodigy ® system
Zoledronic acid

Locations (sample)

Gainesville, Florida, United States|29.65163,-82.32483

Key Eligibility Criteria

Patients 6 months to ≤ 25 years old
Relapsed/Refractory Solid Tumor whom failed or deemed ineligible to receive autologous transplant or if autologous transplant did not offer \>20% c…
neuroblastoma (high risk with relapsed or refractory disease),
relapsed/refractory rhabdomyosarcoma,

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →